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Abstract 
 
Nuclear receptors comprise a large family of ligand-modulated transcription factors that mediate 
cellular responses to small lipophilic molecules including steroids, retinoids, fatty acids and 
exogenous ligands. Orphan nuclear receptors with no known endogenous ligands have been 
discovered to regulate of drug-mediated induction of cytochromes P-450 (CYP), the major drug-
metabolizing enzymes. Here, we report the cloning of a new orphan nuclear receptor from 
chicken, termed chicken xenobiotic receptor (CXR), that is closely related to two mammalian 
xenobiotic-activated receptors, the pregnane X receptor (PXR) and the constitutive androstane 
receptor (CAR). Expression of CXR is restricted to tissues where drug-induction of CYPs 
predominantly occurs, namely liver, kidney, small intestine and colon. Furthermore, CXR binds 
to a previously identified phenobarbital-responsive enhancer unit (PBRU) in the 5’-flanking 
region of the chicken CYP2H1 gene. A variety of drugs, steroids and chemicals activate CXR in 
CV-1 cell transactivation assays. The same agents induce PBRU-dependent reporter gene 
expression and CYP2H1 transcription in a chicken hepatoma cell line. These results provide 
convincing evidence for a major role of CXR in the regulation of CYP2H1 and add a new 
member to the family of xenobiotic-activated orphan nuclear receptors. 
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Introduction 
 
Members of the CYP gene superfamily encode for heme-proteins involved the in oxidative 
metabolism of xenobiotic and endogenous substrates in all species (1). In vertebrates, this 
biotransformation of drugs, steroids and other compounds occurs predominantly in the liver 
whereas extrahepatic tissues such as intestine, kidney, skin, lung or brain play a less prominent 
role (2, 3). Expression of some of these CYPs can be transcriptionally regulated by their 
substrates or other compounds (2-5). Phenobarbital (PB) and other drugs of this class of 
prototypical inducers displays a distinct activation pattern of CYPs. PB-type inducers are a 
family of compounds that are structurally diverse but share the common general characteristics 
of being small and lipophilic molecules (3). 
Steroid hormones possess similar properties in regard to size and hydrophobicity which enables 
them to diffuse into cells and interact with specific intracellular receptors (6, 7). Steroid hormone 
receptors belong to the superfamily of nuclear receptors with conserved structural features. Also 
included in this superfamily are receptors with non-steroid ligands such as thyroid hormone, 
retinoids or fatty acids (8-10). Nuclear receptors with known endogenous ligands are 
distinguished from so-called orphan nuclear receptors for which true endogenous ligands have 
not been identified (6, 8, 11). Steroid hormone receptors bind to cognate DNA recognition 
elements as homodimers in contrast to most of the non-steroid nuclear receptors which 
heterodimerize with the 9-cis retinoic acid receptor (RXR, NR2B group) in order to bind to DNA 
(7, 11). The recognition elements of steroid hormone receptors consist usually of two hexamer 
half-sites arranged as a palindrome. Non-steroid nuclear receptors preferentially bind to two 
hexamer half-sites organized as direct repeat (DR) spaced by a variable number of nucleotides 
(8, 11). 
A link between CYP regulation and nuclear receptors has been established with the discovery of 
the role of several orphan nuclear receptors in the induction of CYPs by xenobiotics. In 
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particular, PXR (NR1I2) and CAR (NR1I3) have been shown to play crucial roles in induction 
of members of the CYP3A and CYP2B subfamilies in human and mouse liver, respectively 
(reviewed in refs. 12-15). PXR and CAR are activated by the same compounds that induce the 
respective CYPs and bind as heterodimers with RXR to response elements in 5’-enhancer 
regions of these genes. Xenobiotic-responsive elements have previously been defined in rat 
CYP2B2 and CYP3A1, mouse Cyp2b10 and human CYP2B6 and CYP3A4 (reviewed in refs. 
13, 15 and 16). These elements are characterized by putative nuclear receptor recognition sites. 
Chicken hepatocytes and, more recently, chicken hepatoma cells have been used extensively as a 
model for elucidating the molecular mechanism of xenobiotic induction (for recent examples, see 
refs. 17 and 18). In chicken liver, CYP2H1 has been identified as one of the major PB-inducible 
genes and a PBRU in its 5’-flanking region has been characterized (17, 19). We have shown that 
a DR-4 element in combination with a nuclear factor-1 (NF-1) site within the CYP2H1 264-bp 
PBRU is required for the response to drugs (19). Similar arrangements of response elements are 
conserved in mouse, rat and human PBRUs. Moreover, drug-activation of human and mouse 
PBRUs in a chicken hepatoma cell line (LMH) strongly suggests conservation of the molecular 
induction mechanisms between chicken and mammals (19). 
In this report, we describe the cloning and functional analysis of a novel chicken orphan nuclear 
receptor that is closely related to the NR1I subfamily of mammalian xenobiotic receptors. We 
have designated the new receptor “chicken xenobiotic receptor” (CXR, NRXXX) because it 
responds to numerous drugs and chemicals and activates a xenobiotic-metabolizing enzyme, 
chicken CYP2H1. We demonstrate that this receptor mediates the transcriptional control of 
CYP2H1 by various drugs and chemicals via the recently described enhancer unit. Sequence 
comparison and activation profiles suggest a close relationship of this transcription factor to the 
mammalian drug-sensing orphan nuclear receptors PXR and CAR. 
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Materials and Methods 

Reagents. Dexamethasone, metyrapone (2-methyl-1,2-di-3-pyridyl-1-propanone), 5-pregnen-3-
ol-20-one-16-carbonitrile (PCN), rifampicin and clotrimazole (1-[o-chlorotrityl]-imidazole) 
were obtained from Sigma, Buchs, Switzerland. Propylisopropylacetamide (PIA) was generously 
provided by Dr. P. Sinclair, VA Hospital, White River Junction, Vt. Glutethimide and -
naphtoflavone were purchased from Aldrich, Buchs, Switzerland. RU486 (mifepristone) was 
obtained from Roussel-UCLAF SA, Paris, France. TCPOBOP (1,4-bis[2-(3,5-
dichloropyridyloxy)]benzene) was a gift from Dr. U. Schmidt, Institute of Toxicology, BAYER 
AG, Wuppertal, Germany. Phenobarbital sodium salt (5-ethyl-5-phenyl-barbituric acid sodium 
salt) was purchased from Fluka, Buchs, Switzerland. Poly(dI-dC)*poly(dI-dC) was from 
Amersham Pharmacia Biotech, Dübendorf, Switzerland. All other reagents and supplies were 
obtained from standard sources. Cell culture media, sera and tissue culture reagents were 
purchased from Life Technologies, Basel, Switzerland unless noted otherwise. 
 
Plasmids. Generation of the reporter plasmid pBLCAT5 containing either the CYP2H1 264-bp 
PBRU or the CYP2H1 264-bp double mutant has previously been described (19). CXR and 
chicken RXR coding regions (20) were generated by PCR, sequenced and subsequently cloned 
into the expression vector pSG5 (Stratagene Europe, Amsterdam, The Netherlands). 
 
Culture and transfection of LMH cells. LMH cells were obtained from the American Type 
Culture Collection and thawed immediately after arrival. Cultivation in William’s E medium and 
transfection with FuGENE 6 Transfection Reagent (Roche Molecular Biochemicals, Rotkreuz, 
Switzerland) were performed as described (19). 
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Isolation of total and poly-A RNA. Tissues from an adult female chicken were frozen in liquid 
nitrogen and homogenized with a glass-Teflon homogenizer at 4°C in TRIZOL reagent (Life 
Technologies, Basel, Switzerland) and total RNA from both chicken tissues and LMH cells was 
obtained according to the suppliers manual. Poly-A RNA was subsequently prepared from total 
RNA with the Oligotex mRNA Midi Kit (Qiagen, Basel, Switzerland) following the protocol 
provided by the manufacturer. 
 
Northern analysis. The 820-bp fragment that was used in screening the chicken liver cDNA 
library described below was 32P-labeled with the Random Primed DNA Labeling Kit (Roche 
Molecular Biochemicals, Rotkreuz, Switzerland) in a Klenow reaction using random hexamer 
primers followed by purification over a Biospin 6 Chromatography Column (Biorad, Glattbrugg, 
Switzerland). 20g of total RNA or 15g of poly-A RNA were loaded onto a 
formaldehyde/agarose gel. Northern blotting was carried out according to standard techniques 
(21). 
 
Gel-mobility shift assays. Chicken CXR and chicken RXR were synthesized in vitro using the 
TNT T7 Quick Coupled Transcription/Translation System (Promega, Catalys AG, Wallisellen, 
Switzerland) according to the manufacturer’s instructions. Probes were labeled with Klenow 
enzyme in the presence of radiolabeled 32P--ATP and the probe was purified over a Biospin 6 
Chromatography Column (Biorad, Glattbrugg, Switzerland). A volume of labeled 
oligonucleotide corresponding to 100’000 cpm was used for each reaction in 10mM Tris (pH 
8.0), 40mM KCl, 0.05% NP-40, 6% glycerol, 1mM dithiothreitol, 0.2g poly(dI-dC)*poly(dI-
dC) and 2.5l of the in vitro synthesized proteins as described previously (22). To test for 
supershifts, 0.5l of monoclonal anti-mouse-RXR rabbit antibody (kindly provided by Dr. P. 
Chambon, IGBMC, Université Louis Pasteur, Illkirch, France) were added to the reaction mix. 
This antibody has been positively tested for cross-reaction with the chicken RXR in Western 
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blots (data not shown). Cold oligonucleotides for competition experiments were added at a 20-
fold molar excess. The mix was incubated for 20 minutes at room temperature and subsequently 
electrophoresed on a 6% polyacrylamide gel in 0.5x Tris-Borate-EDTA buffer followed by 
autoradiography at –70°C. 
 
Transcriptional activation and CAT reporter gene assays. To perform transactivation assays, 
CV-1 cells were kept in DMEM/F12 medium without phenol red, supplemented with 10% 
charcoal-stripped fetal bovine serum and were plated in 6-well dishes at a density of 625’000 
cells per well. A total of 2.5g DNA per well, including 150ng of receptor expression vector, 
400ng of chloramphenicol acetyltransferase (CAT) reporter gene plasmid, 800ng pSV-
galactosidase expression vector (Promega, Catalys AG, Wallisellen, Switzerland) and carrier 
plasmid were transfected and cells exposed to drugs as described in ref. 22. Cell extracts were 
prepared and assayed for CAT using a CAT-ELISA kit (Roche Molecular Biochemicals, 
Rotkreuz, Switzerland). -Galactosidase activities were determined according to ref. 23. CAT 
concentrations were then normalized against -galactosidase values in order to compensate for 
varying transfection efficiencies. 
 
Semiquantitative PCR with the Taqman system. One g of total RNA was reverse-
transcribed with the MMLV reverse transcriptase (Roche Molecular Biochemicals, Rotkreuz, 
Switzerland). PCR was performed using the Taqman PCR Core Reagent Kit (PE Applied 
Biosystems, Rotkreuz, Switzerland) and the transcript level quantitated with an ABI PRISM 
7700 Sequence Detection System (PE Applied Biosystems, Rotkreuz, Switzerland). CYP2H1 
and glyceraldehyde 3-phosphate dehydrogenase transcript levels were measured in separate 
tubes and glyceraldehyde 3-phosphate dehydrogenase was used for normalization of the 
CYP2H1 values as described previously (19).  
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Results 
 
Isolation and classification of the chicken orphan nuclear receptor CXR. The cDNA 
sequences of human and mouse PXR and CAR, respectively, were aligned using the multiple 
alignment algorithm BLOCKS (24) in order to identify conserved sequence stretches. With the 
CODEHOP program, we subsequently screened the aligned sequence stretches for degenerate, 
5’-clamped primers accounting for chicken codon usage (25). The primers 5’-GCC TGC CGG 
CTG CAR AAR TGY YT-3’ and 5’-GGC CCA TCA GCT TGG CRT ANA RRA A-3’ 
amplified an 820-bp fragment in a hot-start, touchdown PCR with LMH cDNA as template. This 
fragment was subcloned and used as a probe in the screening of a chicken liver Lambda ZAP 
phage cDNA library (Stratagene Europe, Amsterdam, The Netherlands). Two different clones 
were obtained, subcloned and sequenced. One clone contained a partial sequence with high 
homology to mammalian orphan nuclear receptors whereas the other clone consisted of a 
different, full-length orphan nuclear receptor cDNA. This full-length clone was denominated 
“CXR” and its DNA and deduced amino acid sequences are depicted in Fig. 1A where the DNA-
binding domain (DBD) is boxed and the conserved cysteins responsible for forming zinc-finger 
domains (26) are shaded. The DBD and ligand-binding domain (LBD) of CXR were compared 
to those of other receptors using the GAP algorithm included in the Wisconsin Package Version 
10.0 software (Genetics Computer Group (GCG), Madison, WI). Similarity between DBDs of 
CXR and other nuclear receptors including mammalian PXRs (27) and CARs (28, 29), xenopus 
benzoate X receptor (BXR, NR1I2, ref. 30) and chicken 1,25-dihydroxyvitamin D3 receptor 
(NR1I1, ref. 31) was between 61% and 67% amino acid identity (Fig. 1B). By comparison, the 
DBDs of chicken progesterone receptor (PR, NR3C3) and estrogen receptor (ER, NR3A1) 
revealed 44.6% and 59.1% amino acid identity with CXR, respectively. The highest similarity to 
the LBD of CXR was observed in human CAR with 56.3% amino acid identity. All of the PXRs 
and mouse CAR exhibit a similarity of about 50% to CXR. When comparing the CXR LBD to 
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the xenopus benzoate X receptor and the chicken 1,25-dihydroxyvitamin D3 receptor, similarities 
dropped to 44.1% and 40.1%, respectively. Moreover, the chicken progesterone and estrogen 
receptor LBDs displayed weak similarity of about 23%. These comparisons position the chicken 
CXR into the NR1 subfamily of orphan nuclear receptors (8, 10). The same conclusion was 
reached when generating phylogenetic trees from multiple alignments of full length amino acid 
sequences with the ClustalW program (Fig. 1C and D). Apart from the receptors used in Fig. 1B, 
the chicken RZR (NR1F2), thyroid hormone receptor (NR1A group), RAR (NR1B3), RAR 
(NR1B1), SF-1 (NR5A1), COUP (NR2F group) and RXR (NR2B3) were included in the trees. 
The branch lengths of the phylogram (Fig. 1C) and the unrooted tree (Fig. 1D) were calculated 
from the number of amino acid substitutions per site. The phylogram depicting the chicken CXR 
within a selection of nuclear receptors also positions CXR into the nuclear receptor subfamily 
NR1 (8, 10). Together, these results suggest that CXR is closely related to mammalian drug-
responsive orphan nuclear receptors of the NR1I group (10). 
 
Chicken CXR is expressed in the main drug-metabolizing tissues. CXR tissue expression was 
examined by Northern blot analysis of various adult chicken tissues (Fig. 2A). Expression of 
CXR was detected in liver, kidney, small intestine and colon but not in any of the other tissues 
(Fig. 2A). Expression levels in liver and kidney were high whereas in small intestine and colon, 
only a faint signal could be detected. Two bands with sizes of about 2kb and 1.4kb, respectively, 
could be observed in both liver and kidney, whereas only the 1.4kb band was observed in small 
intestine and colon. In liver, the 2kb transcript was more abundant than the 1.4kb mRNA while 
in kidney, the 1.4kb band was more prominent than the 2kb mRNA. The chicken LMH 
hepatoma cell line exhibited similar expression levels when compared to adult chicken kidney 
(Fig. 2B). The 1.4kb transcript was clearly detectable in total RNA of LMH cells whereas only a 
very weak signal could be detected for the 2kb band. No change in the level of CXR mRNA was 
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observed in LMH cells after 24 hours of drug-induction with either vehicle, 400M PB, 50M 
dexamethasone or 400M metyrapone (Fig. 2B). 
 
CXR binds to the wildtype chicken CYP2H1 264-bp PBRU. A PB-responsive unit has been 
identified in the chicken CYP2H1 5’-flanking region and a conserved nuclear-receptor 
recognition element has been shown to confer PB-inducibility in this element (19). This nuclear 
receptor recognition element consists of two hexameric core motifs separated by four 
nucleotides, a so-called direct repeat (DR-4). Mutations in either hexamer half-site or in both 
half-sites of this DR-4 abolish PB-induction by this element in reporter gene assays (19). The 
sequences of both the wildtype DR-4 and the double mutation within the 264-bp PBRU are 
shown in Fig. 3A. As nuclear receptors of the NR1 subfamily have been shown to interact 
predominantly with direct repeat elements (8) and CXR was found to be a member of this class, 
a gel-mobility-shift assay was used to determine if CXR binds to the PB-responsive element 
from chicken CYP2H1. Neither in vitro transcribed/translated chicken CXR nor chicken RXR 
alone bound to the radiolabeled 264-bp PBRU (Fig. 3B, lanes 2 and 3). Only the CXR-RXR 
heterodimer binds to the PBRU and this complex could be supershifted with antibodies against 
RXR (Fig. 3B, lanes 4 and 5). A 20-fold molar excess of cold, unlabeled 264-bp PBRU 
competed with the radiolabeled probe for CXR/RXR binding and therefore reduced the shift. 
Unlabeled double mutant 264-bp PBRU competed only weakly with the wildtype 264-bp PBRU 
for CXR/RXR binding (Fig. 3B, lanes 6 and 7) further substantiating the importance of the DR-
4 element in the 264-bp PBRU. 
 
Chicken CXR activates the CYP2H1 264-bp PBRU in CV-1 cells. Transactivation assays 
using a selection of prototypical inducers drugs in CV-1 cells were performed to test whether 
CXR activates the 264-bp PBRU in correlation with the results from gel-mobility shift assays. 
Previous studies have employed a wide variety of drugs to investigate nuclear receptor and CYP 
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activation in chicken and mouse (19, 32). Accordingly, we chose PB (400M) and the PB-like 
inducers PIA (250M), glutethimide (500M) and TCPOBOP (10M), a potent inducer in 
mouse. For comparison, dexamethasone (50M), metyrapone (400M) and RU486 (10M), 
three common CYP3A inducers, and the prototypical CYP1A1 inducer-naphtoflavone (10M) 
were also tested. Furthermore, we were interested in the effects of PCN (50M) and rifampicin 
(100M) because of their species-specific effects on PXR activation and CYP3A expression. 
Clotrimazole (10M) was chosen because it has profound effects on mouse and human PXR and 
CAR (32). CV-1 cells were transfected with chicken CXR and the 264-bp PBRU in a CAT 
reporter gene vector and treated with drugs for 24 hours. None of the drugs had an effect on 
reporter gene expression in absence of CXR (data not shown). The classical PB-type inducers all 
activated CXR and thereby the reporter gene constructs between 2.3- and 3.3-fold (Fig. 4A). 
Metyrapone was the most potent inducer from the class of typical CYP3A inducers showing 3.8-
fold induction. RU486, dexamethasone, PCN and rifampicin however were limited to less than 
1.8-fold activation. The known CYP1A1 inducer -naphtoflavone also strongly activated CXR 
2.9-fold which exceeds the effect found after PB treatment. Finally, clotrimazole was the most 
potent inducer of CXR in these assays resulting in 6-fold induction (Fig. 4A). 
Next, we wanted to investigate the role of CXR on the response element by comparing its 
activation pattern in CV-1 cells to activation of PBRU reporter gene and transcriptional 
activation of CYP2H1 mRNA in a physiological environment. LMH cells were therefore 
transiently transfected with a 264-bp PBRU reporter gene plasmid and were treated with the 
same drugs as mentioned above for 16 hours. CAT levels were measured and normalized against 
total protein content of the differently treated LMH cells. Relative induction levels of CAT 
revealed high activation of the 264-bp PBRU with PB, metyrapone, PIA and glutethimide. 
Dexamethasone, -naphtoflavone, PCN and rifampicin had only minor or no effects. These 
results have in part been published previously (19) and are listed here for comparison. In 
addition, clotrimazole was one of the most potent inducers of the 264-bp PBRU in LMH cells 
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mediating a 20-fold induction. These findings are similar to those for metyrapone, PIA and 
glutethimide. Moreover, RU486 was a weaker inducer (7-fold) when compared to clotrimazole 
whereas TCPOBOP elevated reporter gene levels only 2.7-fold (Fig. 4B). 
With the 264-bp PBRU being only a small part of the CYP2H1 5’-flanking region, overall 
response of these inducers on CYP2H1 mRNA levels was of interest. All of the compounds 
induced CYP2H1 mRNA after 16 hours of drug-exposure. Metyrapone, PIA and glutethimide 
were the strongest activators mediating a 18- to 25-fold increase in CYP2H1 mRNA (Fig. 4C). 
PB and RU486 moderately elevated CYP2H1 transcript levels 12-fold and the remainder of the 
drugs displayed resulted in only about 6-fold activation (Fig. 4C). Taken together, the 
transactivation assays provide unequivocal evidence that CXR is a xenobiotic-responsive 
receptor and that CXR is the major mediator of xenobiotic response through the CYP2H1 PBRU. 
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Discussion 
 
In this report, we describe the cloning and functional analysis of CXR, a novel chicken 
xenobiotic-sensing receptor. CXR shows all of the structural features typical for a member of the 
nuclear receptor superfamily including a conserved DNA-binding domain with two zinc-finger 
domains (26) and a conserved ligand-binding domain (8). CXR heterodimerizes with chicken 
RXR in order to bind to DNA, as evidenced in gel-mobility shift assays. This binding occurs on 
a repeat of hexamer-half-sites derived from the AG(G/T)TCA consensus sequence characteristic 
for all nuclear receptors (8) and binding is abolished by site-directed mutagenesis of these half-
sites. Moreover, these hexamer-half-sites are organized as a direct repeat with a four-basepair 
spacer (DR-4), preferentially bound by non-steroid liganded nuclear receptors (11). The apparent 
lack of an endogenous ligand specifies the CXR at this time to be an orphan nuclear receptor (8, 
11). 
In adult chicken, CXR is expressed in liver, kidney, small intestine and colon. The same tissues 
are known for their role in drug-metabolism and xenobiotic induction of multiple CYP genes 
which constitute the major drug-metabolizing enzyme system (2, 3). In the Northern blot, two 
mRNA bands were detected that showed different distribution in liver compared to kidney and 
intestine. In liver, a 2kb transcript was more abundant when compared to a 1.4kb mRNA 
whereas the ratio was reversed in kidney. Whether these two bands are splice-variants of CXRs 
or represent different, but closely related receptors remains to be investigated. Interestingly, a 
distribution pattern similar to that observed in kidney and intestine was observed in the chicken 
hepatoma cell line LMH. This might be due to the transformed properties of the cell line or to its 
clonal selection. In contrast, chicken liver obviously represents a mixture of different cell types 
of which only a fraction are drug-responsive. 
The binding of CXR as heterodimer with chicken RXR to a recently identified PBRU from 
chicken CYP2H1 (19) suggest an essential role of CXR in CYP regulation. Therefore, in search 
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of activators of CXR, we tested a variety of compounds known to induce different CYPs. The 
activation pattern of CXR in CV-1 cells transactivation assays closely correlated with the 
activation of the 264-bp PBRU in reporter gene assays in LMH cells and paralleled drug-effects 
on CYP2H1 mRNA. Thus, CXR clearly represents the major receptor involved in activating the 
CYP2H1 264-bp PBRU. CYP2H1 mRNA was also induced by some compounds that were 
inactive in reporter gene assays suggesting additional transcriptional control of CYP2H1 by 
other orphan nuclear receptors and other recognition sites in the CYP2H1 5’-flanking region. 
Sequence comparison of the DBD and LBD of CXR to other nuclear receptors surprisingly 
revealed almost equal amino acid identity to several receptors of the group NR1I. This group 
presently consists of the 1,25-dihydroxyvitamin D3 receptor, the xenopus benzoate X receptor 
and of the mammalian xenobiotic-sensing receptors PXR and CAR. Among these, CXR displays 
higher similarity to PXRs and CARs when comparing the full-length amino acid sequences. 
Calculation of the average evolutionary distance between CXR and human and mouse CARs 
revealed 0.474 amino acid substitutions per site and was slightly smaller than the distance 
between CXR and mammalian PXRs (0.52 amino acid substitutions per site). By comparison, 
the average distance between PXRs and CARs is 0.55 amino acid substitutions per site. 
Therefore, CXR is almost equally related to PXRs and CARs at the amino acid sequence level. 
This raises the question of whether CXR represents an ortholog of mammalian PXRs or CARs 
or, alternatively, a new class of xenobiotic-sensing receptors. Usually, nuclear receptor orthologs 
share more than 90% amino acid identity in their DBD and LBD (8). This is different for the 
xenobiotic-sensing receptors PXRs and CARs where the LBD share only about 70% identity 
among mammals alone (32). The CXR sequence revealed 61% to 67% amino acid identity in the 
DBD and 40% to 56% identity in the LBD when compared to other members of the NR1I group 
of nuclear receptors. 
However, the evolutionary distance between CXR, PXR and CAR deviates considerably from 
that of other chicken orthologs of nuclear receptors. Thus, the similarities between the chicken 
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and mammalian farnesoid X receptor (FXR) and liver X receptor (LXR), the receptors for bile-
acids and oxysterols, respectively, are around 94% and 86% amino acid identity in the DBD and 
about 86% and 83% identity in the LBD, respectively (R. Amherd and U. A. Meyer, unpublished 
results). 
We conclude that CXR may well be a new type of xenobiotic-sensing receptors with potential 
orthologs in mammalian genomes. Alternatively, CXR might represent the ancestral gene that 
diverged into CAR and PXR in the course of evolution as an adaptive response to different 
environmental and nutritional pressures. In any case, the basic mechanism of drug-induction of 
enzymes involved in drug-metabolism by orphan nuclear receptors apparently is evolutionary 
conserved over the 300 million years that separate birds from humans. 
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Figure Legends 
 
FIG. 1. CXR is closely related to mammalian drug-responsive orphan nuclear receptors. (A) 
Nucleotide and predicted amino acid sequence of CXR. The putative DBD is boxed and the 
conserved cysteins responsible for forming zinc-finger domains are shaded. (B) Amino acid 
comparison between CXR and a selection of nuclear receptors. The similarity of the DBDs and 
LBDs between CXR and the selected nuclear receptors is indicated as percentage amino acid 
identity. (C) Phylogram of full length amino acid sequences of CXR and related nuclear 
receptors. (D) Unrooted phylogenetic tree of full length amino acid sequences of CXR and 
mammalian CARs and PXRs, respectively. 
The scale-bars for distance measurements represent 0.1 amino acid substitutions per site. 
 
FIG. 2. Expression pattern of CXR. (A) Northern blot analysis of adult chicken tissue. 15g of 
poly-A RNA were used for all tissues. (B) Northern blot analysis of LMH cells. LMH cells were 
induced with either vehicle (Contr), phenobarbital (PB), dexamethasone (Dex) or metyrapone 
(Met) and total RNA was isolated of which 20g were used for Northern blots. 
RNA size markers in number of bases are shown to the left of the blots. 
 
FIG. 3. CXR binds to the CYP2H1 264-bp PBRU. (A) Sequences of the wildtype DR-4 element 
within the 264-bp PBRU and the double mutant with knocked-out hexamer half-sites as adapted 
from ref. 19. (B) Gel-mobility shift assay. Radiolabeled 264-bp PBRU was incubated with in 
vitro transcribed/translated CXR (lane 3-7), chicken RXR (lane 2 and 4-7), anti-RXR antibody 
(lane 5), cold 264-bp PBRU in 20-fold molar excess (lane 6) and cold 264-bp PBRU double 
mutant in 20-fold molar excess as competitors (lane 7), as indicated. Arrows depict the unbound 
probe (c), the complex of CXR, RXR and the probe leading to a shift (b) and the complex of 
CXR, RXR, anti-RXR antibody and the probe resulting in a supershift (a). 
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FIG. 4. Activation of CXR by different drugs. (A) CV-1 cells were co-transfected with an 
expression plasmid for CXR together with a CAT reporter gene plasmid containing the CYP2H1 
264-bp PBRU. Cells were then treated either with vehicle or drugs for 24 hours. Cell extracts 
were analyzed for CAT expression normalized against -galactosidase levels. (B) Activation 
pattern of the CYP2H1 264-bp PBRU. LMH cells were transfected with the 264-bp PBRU in a 
CAT reporter gene plasmid and induced for 16 hours with the same compounds in Fig. 4A. CAT 
levels were determined and normalized against non-treated control cells. Except for the 
previously unpublished results of clotrimazole, RU486 and TCPOBOP, data are adapted from 
ref. 19. (C) Activation pattern of CYP2H1 mRNA. LMH cells were treated with the compounds 
used in Fig. 4A and B for 16 hours. Total RNA was isolated and reverse-transcribed. Relative 
mRNA levels of CYP2H1 standardized against glyceraldehyde 3-phosphate dehydrogenase 
levels were obtained by semiquantitative PCR using the Taqman System. 
Values are the average of three independent experiments and error bars represent standard 
deviations. 
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